CORDIS
EU research results

CORDIS

English EN

Targeted Herpesvirus-derived Oncolytic Vectors for Liver cancer European Network

Project information

Grant agreement ID: 18649

  • Start date

    1 January 2006

  • End date

    31 July 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 3 845 620

  • EU contribution

    € 2 494 460

Coordinated by:

UNIVERSITÉ CLAUDE BERNARD LYON 1

France

Objective

The overall objective of THOVLEN is to develop safe and efficient herpes simplex virus type 1 (HSV-1)-derived oncolytic vectors, designed to strictly target and eradicate human hepatocellular carcinomas (HCC), the most common liver cancer of adults. HSV-1 is certainly one of the most promising viral platforms for the development of improved oncolytic vectors, as anticipated by the unique biological properties of this virus and confirmed by the encouraging results coming from clinical trials in gliomas. However, the first generations of oncolytic HSV-1 vectors have also shown limitations regarding efficacy and safety. New generations of innovative HSV-1 vectors with improved potency and safety are required before the oncolytic strategy using HSV-1 becom es a standard therapeutic reality against cancer, and this is the goal of THOVLEN. One of the most important innovative contributions of our project concerns the overall approach towards the improvement of HSV-1-based oncolytic viruses. Instead of focusi ng on the development of vectors carrying deletions in particular virus genes, we will engineer competent, but replication-restricted, HSV-1 vectors, strictly targeted to HCC. These vectors will combine multiple HCC-targeting approaches, both at the leve l of entry and at the level of gene expression and replication, and will be able to multiply and spread only in HCC, while displaying no virulence in normal healthy tissues. Additionally, an important innovation is related to the ability of the HSV-1 vec tors to permit a sophisticated and flexible combined approach against HCC. That is, in addition to optimizing the oncolytic properties of HSV-1 vectors, THOVLEN will exploit the very large transgenic capability of HSV-1 to generate vectors that will sim ultaneously display multiple and multimodal anti-tumour activities acting either locally or systemically, including combined expression of anti-angiogenic, immune-modulatory, and oncolytic pr

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITÉ CLAUDE BERNARD LYON 1

Address

43 Boulevard Du 11 Novembre 1918
Villeurbanne

France

Participants (7)

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Spain

GENOPOIETIC

France

INSTITUT PASTEUR HELLENIQUE

Greece

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

LYON 1 INGENIERIE

France

NUCLEALP

France

UNIVERSITA DEGLI STUDI DI FERRARA

Italy

Project information

Grant agreement ID: 18649

  • Start date

    1 January 2006

  • End date

    31 July 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 3 845 620

  • EU contribution

    € 2 494 460

Coordinated by:

UNIVERSITÉ CLAUDE BERNARD LYON 1

France